Found 14 hits for monomerid = 230111 Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 300 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 300 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.310 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 370 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.310 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 300 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.310 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 370 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 370 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 300 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230111
(US10106559, Example 39 | US10435415, Example 39 | ...)Show SMILES Cc1c(cccc1-n1c(=O)cc2sccn2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(3.18,-.77,;1.85,-1.54,;.52,-.77,;-.82,-1.54,;-.82,-3.08,;.52,-3.85,;1.85,-3.08,;3.18,-3.85,;3.18,-5.39,;1.85,-6.16,;4.52,-6.16,;5.85,-5.39,;7.31,-5.87,;8.22,-4.62,;7.31,-3.37,;5.85,-3.85,;4.52,-3.08,;4.52,-1.54,;.52,.77,;1.85,1.54,;3.18,.77,;1.85,3.08,;.52,3.85,;.52,5.39,;1.85,6.16,;-.82,6.16,;-.82,3.08,;-2.28,3.56,;-3.19,2.31,;-4.72,2.15,;-5.35,.74,;-4.44,-.5,;-2.91,-.34,;-2.28,1.06,;-.82,1.54,;-6.89,.74,;-8.22,-.03,;-6.49,-.75,;-7.66,2.08,)| Show InChI InChI=1S/C29H23ClN4O4S/c1-14-16(5-4-6-21(14)34-22(35)13-23-33(28(34)37)9-10-39-23)24-19(30)12-18(27(31)36)26-25(24)17-8-7-15(29(2,3)38)11-20(17)32-26/h4-13,32,38H,1-3H3,(H2,31,36) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.340 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |